Content by Lonza

Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 

Lonza strengthens its pharmaceutical quality control portfolio through the acquisition of Redberry, enabling faster and more reliable microbial testing.

Discover how coculture models and CRISPR tools reveal new insights into tumour microenvironments.

Explore how combining human immune and epithelial or cancer cells in vitro enhances predictive power in infectious disease and oncology research.

Join two days of expert-led discussions exploring the tools, targets, and translational strategies driving innovation in oncology drug development.

As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?

Explore the applications of CRISPR-Cas9 technology in therapeutic development for Alzheimer’s disease.

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.

Through periodic testing and proper cell culture management, misidentified and contaminated cell lines can be identified before publication of results or release into the scientific community, thus protecting the validity of research results and the credibility of the biomedical community as a whole

The consequences of using unauthenticated cell lines are already being brought to bear on researchers.